title: Prolonged remission of marginal zone lymphoma in a patient with rheumatoid arthritis treated with anti-tumor necrosis factor agents.
authors.affiliation: Rheumatology Department, Leeds Teaching Hospitals National Health Service (NHS) Trust; s.donaldson@doctors.org.uk.
authors.forename: Sarah L
authors.initials: SL
authors.lastname: Donaldson
authors.affiliation: Haematological Malignancy Diagnostic Service (HMDS) laboratory, St James's Institute of Oncology;
authors.forename: Roger G
authors.initials: RG
authors.lastname: Owen
authors.affiliation: University of Leeds, and Honorary NHS Consultant, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
authors.forename: Dennis G
authors.initials: DG
authors.lastname: McGonagle
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D000069285:Infliximab; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy*; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012074:Remission Induction; D000069283:Rituximab; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab; D003520:Cyclophosphamide; D000069285:Infliximab; D014740:Vidarabine; D000068800:Etanercept; C024352:fludarabine